Is the FDA keeping up with digital health disruption?

fda-blog-700

In today’s digitally driven world, machine learning and artificial intelligence (AI) are being incorporated into more and more medical devices, including the software that is needed to operate them, says Dr Nicola Davies in her monthly FDA Blog for The Pharma Letter.

As machines are now self-learning at a pace that exceeds that of the human mind, device developers are being forced to continuously change products to keep up. This fast-moving industry is also influencing the healthcare industry and the FDA.

What exactly is digital health?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical